The inaugural AACR Drug Discovery and Development (AACR D3) meeting will convene experts to reshape the future of oncology...
Last month, U.S. Rep. Donald Payne Jr. (D-New Jersey), led a roundtable discussion at University Hospital in Newark, New...
Two studies presented at the AACR Annual Meeting 2017 showed that tumors that have mutations in the proteins isocitrate...
On March 23, the U.S. Food and Drug Administration announced the first-ever approval of a treatment for patients with...
Finding a way to therapeutically target the so-called “undruggable” cancer proteins has long been a holy grail of researchers...
The Affordable Care Act, which was enacted in 2010 and recently survived an effort to dismantle it, was the...
Identifying ways to increase the proportion of patients with melanoma who have clinically meaningful and durable responses to immune...
Former Vice President Joe Biden returned to the stage at the American Association for Cancer Research (AACR) Annual Meeting...
Now that a plethora of clinical trials have established positive responses from immunotherapies—immune checkpoint inhibitors, in particular—in patients with...
Earlier this week, the U.S. Food and Drug Administration (FDA) approved the molecularly targeted therapeutic niraparib (Zejula) for the...
April symbolizes a progressive time for cancer researchers around the world. From April 1-5, over 20,000 cancer scientists will...